HCW Biologics Inc.
Index- P/E- EPS (ttm)-0.41 Insider Own0.70% Shs Outstand35.78M Perf Week-6.05%
Market Cap73.97M Forward P/E- EPS next Y-0.47 Insider Trans4.06% Shs Float14.62M Perf Month-13.68%
Income-11.60M PEG- EPS next Q-0.12 Inst Own1.50% Short Float0.22% Perf Quarter-2.42%
Sales3.10M P/S23.86 EPS this Y-245.30% Inst Trans46.75% Short Ratio1.08 Perf Half Y-22.61%
Book/sh1.38 P/B1.46 EPS next Y15.80% ROA- Target Price7.00 Perf Year-
Cash/sh0.96 P/C2.11 EPS next 5Y- ROE- 52W Range1.89 - 7.78 Perf YTD-12.93%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-74.02% Beta-
Dividend %- Quick Ratio26.70 Sales past 5Y- Gross Margin57.40% 52W Low6.88% ATR0.20
Employees44 Current Ratio26.70 Sales Q/Q- Oper. Margin- RSI (14)38.50 Volatility11.21% 9.17%
OptionableNo Debt/Eq0.00 EPS Q/Q38.30% Profit Margin- Rel Volume0.07 Prev Close2.05
ShortableYes LT Debt/Eq0.00 EarningsMar 28 BMO Payout- Avg Volume30.46K Price2.02
Recom2.00 SMA20-6.85% SMA50-16.20% SMA200-27.85% Volume2,086 Change-1.46%
May-23-22 07:30AM  
May-13-22 07:15AM  
May-05-22 07:30AM  
Apr-19-22 07:33AM  
Apr-02-22 01:10PM  
Mar-28-22 07:00AM  
Mar-24-22 08:00AM  
Jan-24-22 09:22AM  
Jan-20-22 09:24AM  
Jan-19-22 08:00AM  
Jan-18-22 06:27AM  
Jan-06-22 07:33AM  
Dec-13-21 07:31AM  
Nov-12-21 07:00AM  
Oct-28-21 02:45PM  
Oct-27-21 07:00AM  
Oct-20-21 07:30AM  
Aug-31-21 09:08AM  
Aug-25-21 09:14AM  
Aug-24-21 07:32AM  
Aug-17-21 07:32AM  
Aug-13-21 07:10AM  
Jul-22-21 04:05PM  
Jul-19-21 06:39PM  
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rhode PeterSee RemarksJan 14Option Exercise0.211,71536048,500Jan 19 05:42 PM
Jiao Jin-anVP of DevelopmentDec 06Buy2.4210,00024,15030,571Dec 07 12:31 PM
Flowers LeeSVP of Business DevelopmentDec 01Option Exercise0.144,28560095,952Dec 03 12:10 PM
Byam RebeccaChief Financial OfficerNov 23Option Exercise0.1427,0003,78089,000Nov 26 12:17 PM